Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$14.28 USD
+0.06 (0.42%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $14.27 -0.01 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
A Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.28 USD
+0.06 (0.42%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $14.27 -0.01 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
A Value D Growth A Momentum B VGM
Zacks News
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alexandria (ARE) Recapitalizes San Diego Property at $981/RSF
by Zacks Equity Research
In sync with its capital-recycling strategy, Alexandria (ARE) and its JV partner divest 70% interest in 9625 Towne Centre Drive, fully leased to Takeda, in San Diego's UTC submarket at $981 per RSF.
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Grifols (GRFS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TAK vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TAK vs. ZTS: Which Stock Is the Better Value Option?
Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
by Zacks Equity Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
by Zacks Equity Research
Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down
by Zacks Equity Research
Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
by Zacks Equity Research
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
by Zacks Equity Research
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree
by Zacks Equity Research
The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.